I am imagining that what they're going for will be biotech problems that can be addressed as software problems in disguise (since they would most certainly be in the right place and connected to the right people for that). Those connections may be worth more than the $2M or from SBIR (assuming they reached phase II), for companies that are fundamentally software shops.
Otherwise, I'm very curious what their strategy is for breaking into the bioscience and technology space in a broader sense, and if that would lead them to opening shop in other metro areas outside of the bay area.
Otherwise, I'm very curious what their strategy is for breaking into the bioscience and technology space in a broader sense, and if that would lead them to opening shop in other metro areas outside of the bay area.